comparemela.com

Page 9 - Ann Chang News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Ultimovacs ASA: Ultimovacs to Launch Phase II Combination Trial of UV1 in Lung Cancer (NSCLC)

Fifth Phase II trial of UV1 in cancer, and largest disease category to dateUV1 will be investigated in combination with the standard-of-care pembrolizumabExpected data read-out by end of 2024 Oslo

Joachim midttunMary ann changHans vassgTerje brustugunFifth phaseCarlos de sousaOdd terje brustugunDrammen hospitalTodd terjeFast trackAnn changAbuse regulationNorwegian securities tradingFinance manager

Ultimovacs Receives Dual FDA Fast Track Designation for UV1 in Advanced Malignant Melanoma

Press release content from Globe Newswire. The AP news staff was not involved in its creation.

Mary ann changHans vassgFast trackRolling reviewBiologic licenseAccelerated approvalPriority reviewCarlos de sousaChief executive officerAnn changLifesci advisorsGlobe newswireUltimovacs asa

Ultimovacs Announces Positive 24-month Follow-up Data from Phase I UV1 Cancer

Press release content from Globe Newswire. The AP news staff was not involved in its creation.

Mary ann changHans vassgChief medical officerCarlos de sousaAnn changLifesci advisorsUltimovacs asaClinical trialsGlobe newswire

Investegate |Ultimovacs ASA Announcements | Ultimovacs ASA: Ultimovacs Begins Dosing of Second Cohort in Phase I TENDU Study Investigating Prostate Cancer-Specific Therapeutic Vaccine

Investegate announcements from Ultimovacs ASA, Ultimovacs Begins Dosing of Second Cohort in Phase I TENDU Study Investigating Prostate Cancer-Specific Therapeutic Vaccine

Mary ann changHans vassgCompany tetanusOslo university hospitalUltimovacs begins dosingSecond cohortTetanus epitope targetingChief medical officerUltimovac tetanus epitope targetingAnn changAbuse regulationNorwegian securities tradingInvestegate announcementsInvestegate company announcementsUltimovacs asaLobenewswire and globenewswire

Ultimovacs ASA: Ultimovacs Begins Dosing of Second Cohort in Phase I TENDU Study Investigating Prostate Cancer-Specific Therapeutic Vaccine

First patient in second cohort dosed with 400 µg of TET vaccineDSMB found no safety concerns for first cohort of three patients at 40 µg dose Oslo, 1 October 2021: Ultimovacs ASA ("Ultimovacs") (OSE

Mary ann changHans vassgCompany tetanusOslo university hospitalTetanus epitope targetingChief medical officerUltimovac tetanus epitope targetingAnn changAbuse regulationNorwegian securities trading

vimarsana © 2020. All Rights Reserved.